• Je něco špatně v tomto záznamu ?

CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer

PA. Jänne, D. Planchard, K. Kobayashi, Y. Cheng, CK. Lee, N. Valdiviezo, K. Laktionov, TY. Yang, Y. Yu, T. Kato, L. Jiang, B. Chewaskulyong, S. Lucien Geater, JM. Maurel, C. Rojas, T. Takahashi, L. Havel, FA. Shepherd, K. Tanaka, D. Ghiorghiu,...

. 2024 ; 42 (7) : 808-820. [pub] 20231202

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc24006969

PURPOSE: We report CNS efficacy of first-line osimertinib plus chemotherapy versus osimertinib monotherapy in patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) from the phase III FLAURA2 study according to baseline CNS metastasis status. METHODS: Patients were randomly assigned to osimertinib plus platinum-pemetrexed (combination) or osimertinib monotherapy until disease progression or discontinuation. Brain scans were performed in all patients at baseline and progression and at scheduled assessments until progression for patients with baseline CNS metastases; scans were assessed by neuroradiologist CNS blinded independent central review (BICR). RESULTS: On the basis of baseline CNS BICR, 118 of 279 (combination) and 104 of 278 (monotherapy) randomly assigned patients had ≥one measurable and/or nonmeasurable CNS lesion and were included in the CNS full analysis set (cFAS); 40 of 118 and 38 of 104 had ≥one measurable target CNS lesion and were included in the post hoc CNS evaluable-for-response set (cEFR). In the cFAS, the hazard ratio (HR) for CNS progression or death was 0.58 (95% CI, 0.33 to 1.01). In patients without baseline CNS metastases, the HR for CNS progression or death was 0.67 (95% CI, 0.43 to 1.04). In the cFAS, CNS objective response rates (ORRs; 95% CI) were 73% (combination; 64 to 81) versus 69% (monotherapy; 59 to 78); 59% versus 43% had CNS complete response (CR). In the cEFR, CNS ORRs (95% CI) were 88% (73 to 96) versus 87% (72 to 96); 48% versus 16% had CNS CR. CONCLUSION: Osimertinib plus platinum-pemetrexed demonstrated improved CNS efficacy compared with osimertinib monotherapy, including delaying CNS progression, irrespective of baseline CNS metastasis status. These data support this combination as a new first-line treatment for patients with EGFR-mutated advanced NSCLC, including those with CNS metastases.

1st Faculty of Medicine Charles University Thomayer Hospital Prague Czech Republic

Department of Clinical Oncology Rondebosch Oncology Centre Cape Town South Africa

Department of Internal Medicine Prince of Songkla University Songkhla Thailand

Department of Life Sciences National Chung Hsing University Taichung Taiwan

Department of Medical Oncology and Hematology University Health Network Princess Margaret Cancer Centre Toronto ON Canada

Department of Medical Oncology Cancer Care Centre St George Hospital Kogarah NSW Australia

Department of Medical Oncology Harbin Medical University Cancer Hospital Harbin China

Department of Medical Oncology Lowe Center for Thoracic Oncology Dana Farber Cancer Institute Boston MA

Department of Medical Oncology Thoracic Group and International Center for Thoracic Cancers Gustave Roussy Villejuif France

Department of Oncology Biometrics AstraZeneca Cambridge United Kingdom

Department of Oncology Instituto Nacional de Enfermedades Neoplasicas Lima Peru

Department of Oncology National Taiwan University Hospital and National Taiwan University Cancer Center National Taiwan University Taipei Taiwan

Department of Respiratory Medicine Saitama Medical University International Medical Center Hidaka Japan

Department of Respiratory Medicine Shanghai Chest Hospital Shanghai Jiao Tong University Shanghai China

Department of Thoracic Oncology Jilin Cancer Hospital Changchun China

Department of Thoracic Oncology Kanagawa Cancer Center Yokohama Japan

Division of Chest Medicine Department of Internal Medicine Taichung Veterans General Hospital Taichung Taiwan

Division of Oncology Department of Internal Medicine Faculty of Medicine Chiang Mai University Chiang Mai Thailand

Division of Thoracic Oncology Shizuoka Cancer Center Shizuoka Japan

Faculty of Medicine Paris Saclay University Paris France

Federal State Budgetary Institution N N Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation Moscow Russia

Late Development Oncology AstraZeneca Cambridge United Kingdom

Late Development Oncology AstraZeneca Gaithersburg MD

Medical Oncology Department Bradford Hill Clinical Research Center Santiago Chile

Research Institute for Diseases of the Chest Graduate School of Medical Sciences Kyushu University Fukuoka Japan

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24006969
003      
CZ-PrNML
005      
20240423155620.0
007      
ta
008      
240412s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1200/JCO.23.02219 $2 doi
035    __
$a (PubMed)38042525
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Jänne, Pasi A $u Department of Medical Oncology, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA $1 https://orcid.org/0000000278214928
245    10
$a CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer / $c PA. Jänne, D. Planchard, K. Kobayashi, Y. Cheng, CK. Lee, N. Valdiviezo, K. Laktionov, TY. Yang, Y. Yu, T. Kato, L. Jiang, B. Chewaskulyong, S. Lucien Geater, JM. Maurel, C. Rojas, T. Takahashi, L. Havel, FA. Shepherd, K. Tanaka, D. Ghiorghiu, NP. Amin, E. Armenteros-Monterroso, X. Huang, AA. Chaudhry, JC. Yang
520    9_
$a PURPOSE: We report CNS efficacy of first-line osimertinib plus chemotherapy versus osimertinib monotherapy in patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) from the phase III FLAURA2 study according to baseline CNS metastasis status. METHODS: Patients were randomly assigned to osimertinib plus platinum-pemetrexed (combination) or osimertinib monotherapy until disease progression or discontinuation. Brain scans were performed in all patients at baseline and progression and at scheduled assessments until progression for patients with baseline CNS metastases; scans were assessed by neuroradiologist CNS blinded independent central review (BICR). RESULTS: On the basis of baseline CNS BICR, 118 of 279 (combination) and 104 of 278 (monotherapy) randomly assigned patients had ≥one measurable and/or nonmeasurable CNS lesion and were included in the CNS full analysis set (cFAS); 40 of 118 and 38 of 104 had ≥one measurable target CNS lesion and were included in the post hoc CNS evaluable-for-response set (cEFR). In the cFAS, the hazard ratio (HR) for CNS progression or death was 0.58 (95% CI, 0.33 to 1.01). In patients without baseline CNS metastases, the HR for CNS progression or death was 0.67 (95% CI, 0.43 to 1.04). In the cFAS, CNS objective response rates (ORRs; 95% CI) were 73% (combination; 64 to 81) versus 69% (monotherapy; 59 to 78); 59% versus 43% had CNS complete response (CR). In the cEFR, CNS ORRs (95% CI) were 88% (73 to 96) versus 87% (72 to 96); 48% versus 16% had CNS CR. CONCLUSION: Osimertinib plus platinum-pemetrexed demonstrated improved CNS efficacy compared with osimertinib monotherapy, including delaying CNS progression, irrespective of baseline CNS metastasis status. These data support this combination as a new first-line treatment for patients with EGFR-mutated advanced NSCLC, including those with CNS metastases.
650    _2
$a lidé $7 D006801
650    12
$a akrylamidy $7 D000178
650    _2
$a aniliny $x terapeutické užití $7 D000814
650    12
$a nemalobuněčný karcinom plic $x farmakoterapie $x genetika $x patologie $7 D002289
650    12
$a nádory centrálního nervového systému $x diagnostické zobrazování $x farmakoterapie $x genetika $7 D016543
650    _2
$a erbB receptory $x genetika $7 D066246
650    12
$a indoly $7 D007211
650    12
$a nádory plic $x farmakoterapie $x genetika $x patologie $7 D008175
650    _2
$a mutace $7 D009154
650    _2
$a pemetrexed $x terapeutické užití $7 D000068437
650    _2
$a platina $x terapeutické užití $7 D010984
650    _2
$a inhibitory proteinkinas $x terapeutické užití $7 D047428
650    12
$a pyrimidiny $7 D011743
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Planchard, David $u Department of Medical Oncology, Thoracic Group and International Center for Thoracic Cancers (CICT), Gustave Roussy, Villejuif, France $u Faculty of Medicine, Paris-Saclay University, Paris, France $1 https://orcid.org/0000000215658310
700    1_
$a Kobayashi, Kunihiko $u Department of Respiratory Medicine, Saitama Medical University International Medical Center, Hidaka, Japan $1 https://orcid.org/0000000264689068
700    1_
$a Cheng, Ying $u Department of Thoracic Oncology, Jilin Cancer Hospital, Changchun, China $1 https://orcid.org/000000019908597X
700    1_
$a Lee, Chee Khoon $u Department of Medical Oncology, Cancer Care Centre, St George Hospital, Kogarah, NSW, Australia $1 https://orcid.org/0000000329559820
700    1_
$a Valdiviezo, Natalia $u Department of Oncology, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru $1 https://orcid.org/0000000243005958
700    1_
$a Laktionov, Konstantin $u Federal State Budgetary Institution "N.N.Blokhin National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation, Moscow, Russia $1 https://orcid.org/000000034469502X
700    1_
$a Yang, Tsung-Ying $u Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan $u Department of Life Sciences, National Chung Hsing University, Taichung, Taiwan
700    1_
$a Yu, Yan $u Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China $1 https://orcid.org/000000015598763X
700    1_
$a Kato, Terufumi $u Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan $1 https://orcid.org/0000000258531424
700    1_
$a Jiang, Liyan $u Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
700    1_
$a Chewaskulyong, Busyamas $u Division of Oncology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand $1 https://orcid.org/0000000340525728
700    1_
$a Lucien Geater, Sarayut $u Department of Internal Medicine, Prince of Songkla University, Songkhla, Thailand $1 https://orcid.org/0000000234948268
700    1_
$a Maurel, Jean-Marc $u Department of Clinical Oncology, Rondebosch Oncology Centre, Cape Town, South Africa
700    1_
$a Rojas, Carlos $u Medical Oncology Department, Bradford Hill Clinical Research Center, Santiago, Chile
700    1_
$a Takahashi, Toshiaki $u Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan $1 https://orcid.org/0000000281882505
700    1_
$a Havel, Libor $u First Faculty of Medicine, Charles University, Thomayer Hospital, Prague, Czech Republic
700    1_
$a Shepherd, Frances A $u Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada
700    1_
$a Tanaka, Kentaro $u Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan $1 https://orcid.org/0000000346024465
700    1_
$a Ghiorghiu, Dana $u Late Development Oncology, AstraZeneca, Cambridge, United Kingdom
700    1_
$a Amin, Neha P $u Late Development Oncology, AstraZeneca, Gaithersburg, MD $1 https://orcid.org/0000000224726522
700    1_
$a Armenteros-Monterroso, Elena $u Late Development Oncology, AstraZeneca, Cambridge, United Kingdom
700    1_
$a Huang, Xiangning $u Department of Oncology Biometrics, AstraZeneca, Cambridge, United Kingdom
700    1_
$a Chaudhry, Ammar Ahmed $u Late Development Oncology, AstraZeneca, Gaithersburg, MD $1 https://orcid.org/0000000221260587
700    1_
$a Yang, James Chih-Hsin $u Department of Oncology, National Taiwan University Hospital and National Taiwan University Cancer Center, National Taiwan University, Taipei, Taiwan $1 https://orcid.org/0000000255865138
773    0_
$w MED00002596 $t Journal of clinical oncology $x 1527-7755 $g Roč. 42, č. 7 (2024), s. 808-820
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38042525 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155616 $b ABA008
999    __
$a ok $b bmc $g 2081135 $s 1216736
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 42 $c 7 $d 808-820 $e 20231202 $i 1527-7755 $m Journal of clinical oncology $n J. clin. Oncol. $x MED00002596
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace